Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.

Huang S, Peet CR, Saker J, Li C, Armstrong EA, Kragh M, Pedersen MW, Harari PM.

Mol Cancer Ther. 2013 Dec;12(12):2772-81. doi: 10.1158/1535-7163.MCT-13-0587. Epub 2013 Oct 15.

2.

Enhanced radiation sensitivity in HPV-positive head and neck cancer.

Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, Peet CR, Lorenz LD, Nickel KP, Klingelhutz AJ, Lambert PF, Harari PM.

Cancer Res. 2013 Aug 1;73(15):4791-800. doi: 10.1158/0008-5472.CAN-13-0587. Epub 2013 Jun 7.

3.

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM.

Cancer Res. 2013 Jan 15;73(2):824-33. doi: 10.1158/0008-5472.CAN-12-1611. Epub 2012 Nov 20.

4.

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL.

Cancer Biol Ther. 2011 Sep 1;12(5):436-46. Epub 2011 Sep 1.

5.

A historical perspective of the EGF receptor and related systems.

Edwin F, Wiepz GJ, Singh R, Peet CR, Chaturvedi D, Bertics PJ, Patel TB.

Methods Mol Biol. 2006;327:1-24. Review.

PMID:
16780209

Supplemental Content

Support Center